RecruitingPhase 1Phase 2NCT03211793

Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis

Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis: the MANUS Trial


Sponsor

UMC Utrecht

Enrollment

20 participants

Start Date

Oct 6, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The MANUS Trial aims to examine the safety, feasibility and potential efficacy of intramuscularly injected allogeneic mesenchymal stromal cells as treatment for digital ulcers of systemic sclerosis.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Established diagnosis of SSc according to the 2013 ACR/EULAR criteria
  • At least one active digital ulcer (painful area, >2 mm in diameter with visible depth and loss of dermis) refractory to intravenous prostacyclins
  • 'Refractory to prostacyclins' is defined as
  • Worsening of ulcer(s) within 1 month after prostacyclins iv
  • No improvement of ulcer(s) after 2 months after prostacyclins iv, as judged by the referring physician
  • Recurrence of exactly the same ulcer(s) (same location) within 3 months after prostacyclins iv
  • Written informed consent

Exclusion Criteria7

  • Ulcer with underlying calcinosis (ruled out by X-ray prior to screening/inclusion)
  • History of neoplasm or malignancy in the past 10 years
  • Pregnancy or unwillingness to use adequate contraception during study
  • Serious known concomitant disease with life expectancy <1 year
  • Uncontrolled hypertension
  • Uncontrolled acute or chronic infection with systemic symptoms (e.g. fever)
  • Follow-up impossible

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMesenchymal stromal cells

8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).

OTHERPlacebo

8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).


Locations(1)

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03211793


Related Trials